Trial Profile
An Open-label, Multiple Dose, Randomized, Three-period Crossover Study in Healthy Subjects to Evaluate the Effect of Co-administration of Oseltamivir (Ro 64-0796) 75 mg Twice Daily and Rimantadine 100 mg Twice Daily on the Pharmacokinetic Properties of Oseltamivir and Rimantadine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2016
Price :
$35
*
At a glance
- Drugs Oseltamivir (Primary) ; Rimantadine (Primary)
- Indications Influenza A virus infections; Influenza B virus infections
- Focus Pharmacokinetics
- Sponsors Roche
- 30 Oct 2011 Results published in the Journal of Clinical Pharmacology.
- 09 Aug 2010 New trial record